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| INTRODUCTION
Venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE), is a leading cause of death for cancer patients. 1 When compared to the general population, patients with cancer are associated with a 4.1-fold risk of thrombosis, and the risk increases by 6.5-fold for those undergoing chemotherapy. 2, 3 Anticoagulation is key for the treatment and prevention of VTE recurrence. Current guidelines recommend anticoagulation with low-molecular-weight heparin (LMWH) monotherapy for at least 3-6 months for treatment and secondary prophylaxis in patients with cancer. 4, 5 Treatment beyond the initial 6 months should also be considered for patients with metastatic disease or those receiving chemotherapy.
These recommendations are based on clinical trials that show superiority of LMWH therapies over vitamin K antagonists (VKAs); however, efficacy superiority reached statistical significance only in one of the clinical trials (the CLOT trial). [6] [7] [8] Vitamin K antagonists, primarily warfarin, are still widely used in clinical practice, but these drugs are difficult to manage in oncology patients:
VKAs are associated with many interactions with other drugs and food.
These interactions can lead to fluctuations in the international normalized ratio (INR), and despite the need for frequent monitoring, VKAs are associated with more bleeding complications than LMWH therapies. [9] [10] [11] A recent meta-analysis of randomized controlled trials also found that direct oral anticoagulants (DOACs) were as effective and safe as warfarin for the treatment of VTE among patients with cancer. 12 In this population, a recent subgroup analysis of the EINSTEIN-DVT and PE randomized clinical trial comparing rivaroxaban to VKAs showed that a single-drug approach with the DOAC rivaroxaban resulted in similar efficacy and safety to VKAs. 13 Little is known about the current utilization of anticoagulant agents in patients with cancer after the approval of DOAC treatments in recent years. The aim of the current study was to describe current treatment patterns and to evaluate patients' persistence to anticoagulant agents. 
| METHODS

| Data source
| Study design
A retrospective cohort design was used to describe current treat- 
| Study endpoints
Persistence on therapy was evaluated as continuous treatment on the index therapy, defined as no gap of more than 60 days between the end of a dispensing days of supply and the start date of the next dispensing, if any. The treatment duration was therefore calculated from the start date of the first dispensing of the index therapy until treatment non-persistence, (not including the 60-day gap) or the end of the follow-up period. Since the number of days of supply of the first refill for oral anticoagulants is usually longer than for injectable anticoagulants, a sensitivity analysis was performed on the subset of patients treated for at least 30 days, thus excluding patients who received an initial treatment of a short duration. This sensitivity analysis assessed whether the differences in persistence between patients treated with injectable anticoagulants vs oral anticoagulants may have been inflated by the higher number of days of supplies of oral anticoagulant dispensings.
| Statistical analysis
All statistical analyses were performed using SAS version 9.1 (SAS Institute, Inc., Cary, NC, USA).
| RESULTS
| Patients characteristics
A total of 2941 newly diagnosed VTE patients with cancer who were treated with anticoagulant agents were identified. Of these, 97%
received anticoagulation with either LMWH (n = 735; 25%), warfarin (n = 1403; 47.7%), or rivaroxaban (n = 709; 24.1%; 
| Treatment patterns and persistence on anticoagulant therapy
The median follow-up period was relatively short in all cohorts, ranging from 4.7 months in the LMWH cohort to 7.1 months in the warfarin cohort. Around one-third of the patients died during the follow-up period: 331 (45.0%), 475 (33.9%), and 219 (30.9%) patients in the LMWH, warfarin, and rivaroxaban cohorts, respectively. Over 60% of patients received anticoagulant treatment in outpatient settings within 7 days post VTE diagnosis (Table 2) .
Approximately one-quarter of patients who initiated LMWH switched to another anticoagulant therapy, while lower switching rates of 8% and 5% were observed for warfarin and rivaroxaban, respectively ( Figure 1 ).
Patients treated with LMWH were less persistent on therapy compared to other treatment groups. Persistence with the initial therapy at 6 and 12 months, respectively, was 37% and 21% for LMWH users, 61% and 35% for warfarin users, and 61% and 36% for rivaroxaban users ( Figure 2 ). The corresponding median treatment duration was 3.3 months for LMWH users and 7.9 months for warfarin and rivaroxaban users. Compared to LMWH users, users of oral agents were 
| DISCUSSION
A large medical and pharmacy claims database was used to describe current treatment patterns and assess patient persistence on anticoagulant therapies for cancer-associated thrombosis. Despite treatment guidelines, recommendations for the use of LMWH monotherapy for the treatment of and as secondary prophylaxis for VTE, The current results showed that persistence on the initial anticoagulant therapy in cancer patients is very low in patients treated with initial LMWH. The persistence rate at 6 months was 37% for patients treated with LMWH and 61% for patients treated with oral therapies.
Studies on persistence with anticoagulant therapy in cancer patients are limited, but similar real-world studies also found that patients receiving injectable anticoagulants were less persistent than those treated with oral anticoagulants. 24 This might also reflect the treatment patterns of physicians, prescribing LMWH for only short periods despite treatment recommendations among active cancer patients.
Additionally, in patients with risk factors for VTE, including patients with cancer-related VTE, adherence on warfarin was also reported to be low: 77% of patients treated with warfarin had a proportion of days covered lower than 0.8 during the year after initiation of therapy. reliance on the real-world utilization of LMWH, warfarin, and rivaroxaban use in patients with cancer, and it is consistent with prior similar analyses.
This real-world analysis of current treatment patterns for cancerassociated thrombosis showed that warfarin is still the most commonly used anticoagulant and that rivaroxaban is as commonly used as LMWH, despite guideline recommendations. Patients on LMWH had a significantly lower persistence and a shorter duration of treatment than patients on warfarin or rivaroxaban during the course of treatment. Patients initiating on these oral agents are at significantly lower risk to discontinue therapy relative to LMWH. Furthermore, more patients switched from LMWH to other anticoagulants compared with patients who had started on warfarin or rivaroxaban treatments.
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